40 results about "Heart transplantation" patented technology

The present inventors assessed the effect of anti-IL-6 receptor antibodies in suppressing chronic rejection reaction. They assessed the effect of anti-mouse IL-6 receptor antibody (MR16-1) administration in suppressing the chronic rejection reaction using a mouse model for post-heart-transplantation chronic rejection. The result of histopathological analysis of transplanted hearts extirpated 60 days after transplantation revealed that fibrosis of myocardium and vascular stenotic lesions, which are pathological conditions characteristic of the chronic rejection reaction, were significantly suppressed in the MR16-1-treated group as compared to the control group. Thus, MR16-1 administration was demonstrated to have the effect of suppressing chronic rejection reaction. Specifically, the present inventors discovered for the first time that the rejection reaction in the chronic phase after organ transplantation was suppressed by administering an anti-IL-6 receptor antibody.

A method for treating cardiac failure such as congestive heart failure by application of hypothermia. Hypothermia may be applied by endovascular cooling using a heat exchange catheter circulating heat exchange fluid between an external heat exchanger controlled using temperature feedback from a temperature probe on or in the patient to cool the heart to a sufficiently low temperature for a sufficient length of time to increase cardiac output and improve the vascular condition of the patient. The patient may be maintained in the hypothermic condition for a period of time and is then re-warmed slowly and controllably. The endovascular temperature management may be controlled automatically in response to a temperature probe on the patient, and shivering while the patient is cool may be combated using surface warming and anti-shivering drugs. The method is applicable to treat congestive heart failure and may be used repeatedly on the same patient to restore that patient to adequate heart function when the vascular condition of that patient has become unacceptable. The method may be used to maintain a patient until a heart transplant becomes available. The method may be used to stabilize a patient's condition to allow needed surgery or intervention. The method may be used in conjunction with other treatments including drugs, balloon pumps, pacing devices and ventricular assist devices.

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).

Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and/or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

Improved methods for heart transplant are described. The methods utilize an allograft comprising a layer of amnion to improve the performance and reduce complications of the heart transplant surgery and the allograft has a pre-made size and shape suitable for the application.

The invention discloses an immune inhibiting drug and application based on ring-icariin in the formula I, which is characterized by the following: inhibiting immuse exclusive reaction in the organ transplanting course, modifying transplanted organ function.

The invention provides application of nitidine chloride to the preparation of a medicament for resisting autoimmunity disease and graft versus host disease. An experiment shows that the nitidine chloride can inhibit the proliferation of human dendritic cells in vitro, inhibit the human dendritic cells from promoting the proliferation reaction of allogeneic T cells and strengthen the capacity of secreting interleukin 10 of the human dendritic cells. Meanwhile, in an experimental autoimmunity disease cerebrospinal meningitis model, when used in vivo, the nitidine chloride can reduce the average clinical score of a mouse and inhibit the spinal marrow infiltration degree of monocytes and can obviously improve the secretion level of the interleukin 10 in the blood serum of the mouse. In a heart transplantation experiment, when used in vivo, the nitidine chloride can prolong the survival time of the transplanted heart. In a delayed type hypersensitivity reaction model, when used in vivo, the nitidine chloride can reduce the ear swelling degree of the mouse. Both in-vivo and in-vitro results show that the nitidine chloride has a certain effect of resisting the autoimmunity disease and the graft versus host disease. The medicament is a preparation which consists of the nitidine chloride serving as an active ingredient and a pharmaceutical carrier. The medicament can be prepared into an oral preparation, an injection, a suppository or an external preparation and the like.

A hemodynamic flow assist device includes a miniature pump, a basket-like cage enclosing and supporting the pump, and a motor to drive the pump. The device is implanted and retrieved in a minimally invasive manner via percutaneous access to a patient's artery. The device has a first, collapsed configuration to assist in implantation and a second, expanded configuration once deployed and active. The device is deployed within a patient's aorta and is secured in place via a self-expanding cage which engages the inner wall of the aorta. The device includes a helical screw pump with self-expanding blades, sensors, and anchoring structures. Also disclosed is a retrieval device to remove the hemodynamic flow assist device once it is no longer needed by the patient and an arterial closure device to close the artery access point after implantation and removal of the hemodynamic flow assist device. The hemodynamic flow assist device helps to increase blood flow in patients suffering from congestive heart failure and awaiting heart transplant.

Described herein are compositions and methods particularly useful in the medical arts. The compositions and methods may be used in connection with the preservation of a portion of a mammal, for example, tissues, organs, appendages, limbs, extremities, stem cells, myocytes, bone marrow, skeletal muscle as well as an array of other medical procedures, such as cardiac surgery, transplantation and/or preservation. In various embodiments, the inventive composition may be hyperoxygenated and be formulated to resemble the biochemistries of natural intracellular fluids. The inventive composition includes active ingredients to reduce ischemic, hypothermic and reperfusion injury during transplantation, thereby resulting in improved post-transplant graft function and quality, when used in connection with organ transplantation and storage procedures, for example cardiac transplantation.

The invention provides application of lariciresinol to preparing a medicament for resisting an autoimmune disease and a graft rejection disease. An experiment discovers that: the lariciresinol can inhibit human dendritic cell proliferation in vitro and inhibit the capability of human dendritic cells of promoting allogeneic T cell proliferation reaction and enhancing the secretion of interleukin 10. Meanwhile, in an experimental autoimmune myelomeningitis model, the lariciresinol is applied in vivo, so that an average clinical score of mice can be reduced and the spinal infiltration of mononuclear cells is inhibited. In a heart transplant experiment, the lariciresinol is applied in vivo, so that the survival time of a transplanted heart is prolonged. In a delayed hypersensitivity model, the lariciresinol is applied in vivo, so that the auricle swelling degree of the mice can be reduced. In-vivo and in-vitro results both show that: the lariciresinol has the certain effect of resisting the autoimmune disease and graft rejection disease. The medicament is a preparation which consists of the lariciresinol serving as an active ingredient and a medical carrier, and comprises an oral preparation, an injection, a suppository, an external preparation and the like.

The invention discloses a chimeric combined vascular anastomosis device. The chimeric combined vascular anastomosis device comprises two parts, namely, an acceptor end and a donor end, the acceptor end and the donor end are of annular structures, the sizes of the acceptor end and the donor end are matched with blood vessels of the acceptor end and blood vessels of the donor end respectively, a chimeric mechanism is arranged on the acceptor end and the donor end, and close gomphosis of the acceptor end and the donor end can be achieved through the chimeric mechanism. The vascular anastomosis device is suitable for vascular anastomosis in the operative processes of organ transplantation such as liver transplantation and heart transplantation. In the operative processes of the organ transplantation, fast, accurate and reliable vascular anastomosis can be achieved, operative process is greatly simplified, the operative difficulty and labor strength of operators are lowered, no organ period and intraoperative blood vessel blocking time are shortened, the operative success rate is improved, and the postoperative complication is lowered.

The present invention provides methods of treatment and prevention of early cardiac and early cardiovascular diseases, for instance of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

The invention discloses an intractable heart failure left ventricular function auxiliary device. Various straws and cavity tunnels are designed in a suction head, outer sucking holes are formed in thelower wall and the outer side of the suction head, a straw is led to a proximal end conical cavity inwards, a one-way valve is designed at a position communicated with the cavity in a pipeline of thestraw, the straw is communicated with an inner cavity of an air bag through the one-way valve, a single channel is connected with the drop-shaped suction head in a straw valve crossing section, a distal end is communicated with an air bag chamber, four one-way valves are arranged on the outer wall of the trapezoid side surface of a capsule and communicated with an inner cavity of the air bag chamber through channels, conical upper end is connected with an air-space tunnel through a trachea, branch tracheae pass the air bag chamber downwards and are opened on the inner side of the wall of theair bag and converged into a main trachea upwards, the main trachea is communicated with outside thought an artery, and the lower end of a guide wire is communicated with the drop-shaped suction head.The device has the advantages that the device can continuously work under the condition of left ventricular function loss, and time is bought for clinical rescue or heart transplantation.

The invention relates to the field of cardiac auxiliary circulation, in particular to a minimally invasive catheter type synchronous cardiac auxiliary device and a use method thereof. An execution portion comprises an inner cavity, the inner cavity is enclosed by a cavity wall to form an entirety with a cylindrical shape, and the formed inner cavity enclosed by the cavity wall is used for placingan intermediate gasbag; the front and back ends of the inner cavity are respectively provided with a front end gasbag and a back end gasbag which have valve effects, the front gasbag, the back end gasbag and the intermediate gasbag are respectively and externally connected with an air bump through flexible tubes, and an execution piece is controlled by a control module and is matched with a patient cardiac impluse characteristic to boost blood in the left ventricular to the aorta. According to the minimally invasive catheter type synchronous cardiac auxiliary device, it can be achieved that the blood in the left ventricular can be boosted to the aorta, significant effects are performed on patient recovery after cardiovascular surgery, heart transplantation transition or replacement, myocardial function recovery and permanent treatment of cardiac failure, the cost is low, the device structure is simple and compact, and it is convenient to popularize and promote the device.

The invention relates to a method for screening an optimal gene combination of a heterograft donor pig and belongs to the technical field of animal biologics. By taking human fibroblast as a study target, an in-vitro compatibility evaluation method for human fibroblast is established, results of reported pig fibroblast modified with heart or other genes with long transplantation survival times canbe verified by using the method, and relatively applicable complement adjustment factors, immune response factors and anticoagulation factors can be screened; on the basis of GTKO (Gene Transferase Knockout), the factors are combined and are subjected to fixed knock-in or knockout, pig fibroblast of different multi-factor combinations is subjected to early-stage screening, then cells of more thanthree optimal gene combinations are recloned, cloned pigs are subjected to heart transplantation of pig-non-primate animals, and the reliability of the screening method can be verified. By adopting the method, an optimal gene combination can be evaluated without the basis that a gene combination modified pig is available, so that the gene combination screening time and the investment cost can begreatly reduced, and the method has great significances in development of real heterograft donor pigs.

The invention provides a novel use of a substance for detecting content of soluble ST2 (sST2) protein and a novel use of taking the soluble ST2 (sST2) as a blood serum marker. The sST2 which is takenas the blood serum marker can be independently applied to risk stratification of a child patient with dilated cardiomyopathy (DCM) and predication of an adverse event (all-cause mortality/ heart transplantation/ rehospitalization as a result of congestive heart failure); meanwhile, the sST2 which is taken as the blood serum marker can improve predication ability of a conventional marker-BNP, can be used for monitoring DCM child patient disease progression and is not affected by a renal function and BMI. The application provides scientific basis for monitoring risk stratification, prognosis anddisease progression of the patient with dilated cardiomyopathy, greatly and positively intervenes a decision opportunity clinically before the adverse event occurs, makes up the research and clinicalapplication blank of the medical industry, and has great potential and value of clinical and market application.

The invention discloses the application of quercetin in preparing medicaments for treating organ transplant rejection reactions. The quercetin can be used for treating rejection reactions generated by inhibited tissue organs, such as liver, kidney, bone marrow, cornea, skin and heart transplantation. The invention also relates to the preparation of quercetin compositions.

The invention discloses a heart auxiliary stent balloon, which belongs to the field of organ auxiliary devices. The heart auxiliary stent balloon comprises a stent made of a memory metal and a capsulefilm made of an elastic material, the capsule film is sleeved at one end of the stent to form an air bag; an air duct communicated with the interior of the air bag is arranged in the stent; wherein aplurality of groups of access channels are arranged in the stent, and each group of access channels consists of a channel entry section and a channel exit section which are arranged side by side andhave one communicated ends; and the end parts of the ends, communicated with each other, of the channel entry section and the channel exit section in each group of access channels extend into different positions of the stent. The heart auxiliary stent balloon is implanted through percutaneous puncture, is easy to disassemble and assemble, simulates a physiological working state of the heart to a maximum extent, plays a role in heart assistance, is beneficial to recovery of the physiological function of damaged myocardium and improvement of the living quality of a patient, and can be used in atransition period before heart transplantation. The method is simple, cost is saved for the patient, and safety of the patient is guaranteed.

The present invention relates to novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (IGF-1). More specifically, the present invention relates to method for improving cardiovascular function and symptoms in a patient with chronic severe heart failure by administering IGF-1 to the patient for a certain period, wherein no options for treating the disorder the patient remain other than heart transplantation.

The present invention provides methods which may effectively be used in the treatment and prevention of early cardiac and early cardiovascular diseases, for example of ischemic origin, such as left ventricular hypertrophy, coronary artery disease, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), diastolic dysfunction and systolic dysfunction, as well as improving the success of heart transplantations, through administration of glycogen phosphorylase inhibitor compounds.

The invention provides an application of JQ1 in preparing organ transplantation immunological rejection inhibiting medicines, in particular an application in preparing medicines for preventing and treating cardiac transplantation immunological rejection. Based upon experiments, it is proved that the survival time of transplanted hearts of an allogeneic mice (C57BL/6 to BALB/c) in a control group is 7-10 days, while the survival time of transplanted hearts of mice applied with the JQ1 can reach 25 days to the greatest extent, indicating that the JQ1 provided by the invention is beneficial for reducing an alloimmunity reaction and prolonging the survival of transplants. The JQ1, as a novel small-molecule inhibitor, can solve the problem that transplanted organs are low in survival rate for along time due to rejection, and the JQ1 can offer a basis for preparing organ transplantation immunological rejection inhibiting preparations; therefore, an effective approach is provided for treating such chronic end-stage diseases such as liver diseases, renal diseases, cardiac diseases and the like.

The invention discloses a polypeptide analog for resisting heart implant vasculopathy, and a corresponding cDNA (complementary deoxyribonucleic acid) and application thereof. On the basis of the establishment of the TIMP-1 and MMP-14 interaction structure field in CAV, the invention provides a method for producing a recombinant polypeptide analog myc HisA-TIMP-1[triangle102-217aa] by a gene engineering process. The polypeptide analog has the advantages of high expression efficiency and simple purification technique, and is beneficial to further large-scale preparation. The polypeptide analog can promote the interaction between TIMP-1 and MMP-14, inhibit the VSMC transfer after heart transplantation and inhibit the CAV from generation and development. The polypeptide analog can provide theoretical references for searching for effective intervention target spots for CAV and developing new therapeutic drugs. The polypeptide analog has very important development prospects for implementing long-term survival of heartmen after CAV clinical therapy.